Clinical Trials Logo

Chickenpox clinical trials

View clinical trials related to Chickenpox.

Filter by:

NCT ID: NCT05630846 Active, not recruiting - Clinical trials for Measles; Mumps; Rubella; Chickenpox

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

Start date: December 14, 2022
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.

NCT ID: NCT05604911 Recruiting - Clinical trials for Kidney Transplant; Complications

Herpes Virus Infections in Kidney Transplant Patients

HINT
Start date: January 1, 2023
Phase:
Study type: Observational

Kidney transplant recipients are at increased risk of infections, including Varicella-zoster virus (VZV) infections. Vaccination against VZV is routinely offered to all kidney transplant recipients and candidates in Denmark. In this exploratory observational study, the VZV specific immune response in kidney transplant candidates and recipients will be characterized at different time points in relation to transplantation, vaccination and infections. More knowledge on the immune reaction to transplantation, VZV vaccination and VZV infections may provide improved strategies for prevention and treatment of VZV infections in kidney transplant candidates and recipients.

NCT ID: NCT05526820 Completed - Varicella Clinical Trials

A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine

Start date: April 8, 2021
Phase: Phase 4
Study type: Interventional

This study is a randomized and controlled Phase IV clinical trial.The purpose of this study is to evaluate the immunogenicity and safety of combined immunization with live attenuated varicella vaccine and inactivated hepatitis A vaccine in children aged 12-15 months.

NCT ID: NCT05470855 Active, not recruiting - Varicella Clinical Trials

Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province

Start date: July 6, 2022
Phase: Phase 4
Study type: Interventional

This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the protective effect of varicella vaccine in children aged 1-12 years and the correlation between varicella antibody and protective effect,to evaluate the immunogenicity and safety of varicella vaccine in children aged 1-12 years.

NCT ID: NCT05460429 Recruiting - Varicella Clinical Trials

Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus

Start date: July 30, 2022
Phase: Phase 4
Study type: Interventional

This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity and safety of a single dose of varicella vaccine in healthy children aged 1-6 years with different varicella immunization histories, to evaluate the antibody level of varicella-zoster virus in healthy people aged 0-59 years in Zhejiang Province.

NCT ID: NCT05422508 Recruiting - Varicella Clinical Trials

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Start date: July 5, 2022
Phase: Phase 2
Study type: Interventional

- Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination - Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination

NCT ID: NCT05158777 Completed - Varicella Clinical Trials

Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old

Start date: February 13, 2022
Phase: Phase 3
Study type: Interventional

This is a randomized, blind, controlled clinical trial of live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd. The purpose of this study is to evaluate the immunogenicity and safety of a two doses vaccination of investigational vaccine with 0,28 day and 0,56 day immunization schedule in population aged ≥13 years old.

NCT ID: NCT05150392 Completed - Varicella Clinical Trials

An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization

Start date: July 11, 2018
Phase: Phase 3
Study type: Interventional

This is an open-labelled clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunity persistence of the single-dose primary immunization of live attenuated varicella vaccine on different time points ,and the safety and immunogenicity after the booster immunization

NCT ID: NCT05095701 Enrolling by invitation - Varicella Clinical Trials

An Immunity Persistence Study of Live Attenuated Varicella Vaccine

Start date: December 18, 2021
Phase: Phase 4
Study type: Interventional

This an open phase Ⅳ clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunity persistence of live attenuated varicella vaccine at 5 and 8 years after primary immunization with live attenuated varicella vaccine.

NCT ID: NCT05084508 Active, not recruiting - Chickenpox Clinical Trials

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Start date: February 3, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess immune response and safety of various potencies of an investigational chickenpox vaccine given to healthy children 12 to 15 months of age.